| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 10.48 | 15.70 | 24.71 | 12.62 |
| Receivables | 0.95 | 0.23 | — | 0.46 |
| Inventory | — | — | — | — |
| Other | — | — | — | 0.84 |
| 17.54 | 18.45 | 27.06 | 16.69 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 3.39 | 1.46 | 1.20 | 0.76 |
| ST’ Debt | — | — | — | — |
| Other | 13.74 | 16.57 | 19.66 | 14.97 |
| 20.48 | 21.61 | 23.69 | 16.92 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.15 | 0.19 | — | — |
—
|
| ’25 | 0.03 | (0.02) | 0.00 | 1.02 |
1.03
|
| ’24 | 0.01 | 0.02 | 0.04 | (0.06) |
0.01
|
| ’23 | — | — | 1.00 | 1.81 |
2.81
|
| ’22 | — | 10.00 | — | — |
10.00
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (5.52) | (6.78) | — | — |
—
|
| ’25 | (5.47) | (5.42) | (0.44) | 1.44 |
(9.89)
|
| ’24 | (6.81) | 12.90 | (5.92) | 5.31 |
5.47
|
| ’23 | (16.12) | (6.59) | (7.97) | (8.18) |
(38.86)
|
| ’22 | (12.34) | (8.45) | 8.60 | (5.90) |
(18.09)
|
| ’21 | (8.38) | (11.79) | 1.32 | (9.92) |
(28.76)
|
| ’20 | (6.60) | (4.09) | (5.36) | (9.19) |
(25.23)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (5.52) | (6.86) | — | — |
—
|
| ’25 | (5.63) | (5.26) | (0.62) | 1.24 |
(10.27)
|
| ’24 | (6.82) | 12.62 | (5.64) | 4.74 |
4.90
|
| ’23 | (16.12) | (6.59) | (8.00) | (8.79) |
(39.49)
|
| ’22 | (12.35) | (8.45) | 8.55 | (5.90) |
(18.15)
|
| ’21 | (8.38) | (11.79) | 1.31 | (9.92) |
(28.78)
|
| ’20 | (6.60) | (4.10) | (5.36) | (9.20) |
(25.25)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (0.20) | (0.20) | — | — |
—
|
| ’25 | (0.50) | (0.45) | (0.28) | (0.02) |
(1.20)
|
| ’24 | (0.84) | 1.52 | (0.55) | (0.64) |
(0.48)
|
| ’23 | (1.08) | (1.20) | (1.08) | (0.72) |
(4.20)
|
| ’22 | (1.20) | 0.00 | (0.96) | (2.28) |
(4.44)
|
| ’21 | (1.92) | (2.16) | (2.16) | (2.16) |
(7.56)
|
| ’20 | (2.16) | (3.24) | (2.88) | (2.64) |
(10.92)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | 9.84 | 3.24 | 2.67 | 1.61 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 25.20 | 16.80 | 7.56 | 9.19 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 30 | 26 | 23 | 24 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.33 | 0.11 | 0.00 | 0.04 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | — | — | — | — | — | 10.00 | 2.81 | 0.01 | 1.03 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡ | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 100.00% | 100.00% | 100.00% | 71.29% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (30.95) | (30.16) | (4.05) | (13.40) | ‡‡‡‡‡ | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | (309.48%) | (1,074.16%) | (41,363.27%) | (1,300.65%) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (30.95) | (30.16) | (4.05) | (13.40) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.02 | 0.04 | 0.04 | 1.63 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 1.42 | 0.39 | 0.00 | 0.09 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (4.44) | (4.20) | (0.48) | (1.20) | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.57) | (5.34) | 0.64 | (0.88) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | (0.09) | (0.07) | (0.03) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.58) | (5.43) | 0.58 | (0.92) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.58 | (0.69) | (0.71) | 0.25 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.04 | 7.28 | 8.50 | 11.18 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡ | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| ‡‡‡ | — | — | — | — | — | 0.00 | 2.24 | 2,705.33 | 20.94 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡ | — | — | — | — | — | 6.61 | 0.00 | 0.00 | 7.59 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡ | — | — | — | — | — | 0.00 | 1.44 | 1,125.70 | (2.70) | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | — | — | — | — | — | (2.16) | (0.47) | 2.25 | 0.27 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (18.09) | (38.86) | 5.47 | (9.89) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.06) | (0.63) | (0.57) | (0.39) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (18.15) | (39.49) | 4.90 | (10.27) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.41 | (2.94) | (3.17) | 3.38 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.49 | — | — | — | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (34.18) | (10.48) | (15.70) | (24.71) | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 11.11 | (5.05) | (6.01) | 2.84 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (62.12%) | (92.65%) | (18.69%) | (49.10%) | ‡‡‡‡‡ | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (124.12%) | (994.69%) | 73.30% | 845.52% | ‡‡‡‡‡ | — | — |
ROE
|
Dare Bioscience (DARE), a trailblazing women’s health biotech, dangles blockbuster potential with analyst price targets signaling 370% to over 600% upside from recent lows, fueled by a promising pipeline including the FDA-approved XACIATO for bacterial vaginosis and advancing candidates like DARE-VVA. Yet, this high-reward play collides with harsh realities: a decade of relentless cash burn, explosive share dilution (up 12,100% since 2016 to 8.5 million shares), and revenue that rocketed to $10 million in 2022 before plummeting 99.7% to just $9,800 in 2024, leaving revenue per employee at a dismal $426 amid a tiny 23-person team.
Analysts envision a dramatic turnaround, projecting revenues exploding 7,769% to $771,000 in 2025, then surging to $65 million by 2027, flipping losses to profitability with EPS hitting $0.91—potentially normalizing sky-high valuations like 1,126x EV/Sales. Bright spots include 100% gross margins, positive free cash flow, and low debt, but red flags wave: negative equity, no insider buying in over a year, and commercialization stumbles echoing biotech pitfalls.
Can DARE ignite the women’s health revolution analysts crave, or will dilution and demand fragility cap the rally? With catalysts like Phase 3 readouts looming, this speculative gem tempts growth seekers ready for volatility—dive into the full analysis for the unvarnished path to potential moonshot gains.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.